A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
Open Access
- 10 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 11 (1), 1-14
- https://doi.org/10.1038/s41467-020-16735-2
Abstract
Personalized cancer treatments using combinations of drugs with a synergistic effect is attractive but proves to be highly challenging. Here we present an approach to uncover the efficacy of drug combinations based on the analysis of mono-drug effects. For this we used dose-response data from pharmacogenomic encyclopedias and represent these as a drug atlas. The drug atlas represents the relations between drug effects and allows to identify independent processes for which the tumor might be particularly vulnerable when attacked by two drugs. Our approach enables the prediction of combination-therapy which can be linked to tumor-driving mutations. By using this strategy, we can uncover potential effective drug combinations on a pan-cancer scale. Predicted synergies are provided and have been validated in glioblastoma, breast cancer, melanoma and leukemia mouse-models, resulting in therapeutic synergy in 75% of the tested models. This indicates that we can accurately predict effective drug combinations with translational value.Funding Information
- KWF Kankerbestrijding (KWF-4874 and KWF-11038)
- Brain Tumour Charity (488097)
This publication has 70 references indexed in Scilit:
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsThe New England Journal of Medicine, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerThe New England Journal of Medicine, 2012
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- Mutual exclusivity analysis identifies oncogenic network modulesGenome Research, 2011
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- MEK1 mutations confer resistance to MEK and B-RAF inhibitionProceedings of the National Academy of Sciences of the United States of America, 2009
- Chemical combination effects predict connectivity in biological systemsMolecular Systems Biology, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2006